Funding
The funding for the study was provided jointly by the companies Janssen Pharmaceuticals and DayTwo. Janssen is one of the investors of DayTwo. E.S. is a regular paid consultant for DayTwo. No other potential conflicts of interest relevant to this article were reported. No pharmaceutical manufacturers or other companies from the industry, including the sponsors mentioned above, contributed to the planning, design or conduct of the trial. The analyses presented here were performed by the Weizmann Institute of Science scientists independent of the sponsors. The scientists have the right to publish regardless of the outcome.